BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021; 27(47): 8069-8080 [PMID: 35068855 DOI: 10.3748/wjg.v27.i47.8069]
URL: https://www.wjgnet.com/2307-8960/full/v27/i47/8069.htm
Number Citing Articles
1
Qiao Ke, Fuli Xin, Huipeng Fang, Yongyi Zeng, Lei Wang, Jingfeng Liu. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic ReviewFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.913464
2
Qianyi Lin, Dexiong Chen, Kangde Li, Xiaomin Fan, Qi Cai, Weihong Lin, Chunhong Qin, Tao He. Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality TherapyFrontiers in Radiology 2022; 2 doi: 10.3389/fradi.2022.858963
3
Jing-Nan Xue, Yan-Yu Wang, Yun-Chao Wang, Nan Zhang, Long-Hao Zhang, Zheng-Hui Lu, Li-Jin Zhao, Hai-Tao Zhao. Novel cellular therapies for hepatobiliary malignanciesHepatobiliary & Pancreatic Diseases International 2022; 21(5): 450 doi: 10.1016/j.hbpd.2022.08.014
4
Bowen Chen, Jin Lei, Haitao Zhao, Jinghui Dong, Zhen Zeng, Yinyin Li, Lingxiang Yu, Lin Zhou, Aiying Jia, Yinying Lu, Jiamin Cheng. Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective StudyJournal of Hepatocellular Carcinoma 2022; : 1171 doi: 10.2147/JHC.S387254
5
Yong-Guang Wei, Hao Su, Zi-li Lv, Xi-Wen Liao, Zhi-Ming Zeng, Yu-Xuan Jia, Hua-Sheng Huang, Xiao-Qiang Shen, Guang-Zhi Zhu, Chuang-Ye Han, Xin-Ping Ye, Tao Peng. Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomyFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1165538
6
Renguo Guan, Chengyou Yu, Shaohua Li, Jie Mei, Wei Wei, Rongping Guo. A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinomaFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.998534
7
Kang Chen, Cheng-Piao Luo, De-Xiang Ge, Ke-Lin Wang, Qin Luo, Yan-Zhi Li, Xue-Mei You, Bang-De Xiang, Le-Qun Li, Liang Ma, Jian-Hong Zhong. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinomaFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.946693
8
Qingwei Zhu, Wei Rao, Junyu Huo, Zixiang Li, Song Wang, Wensheng Qiu, Ge Guan, Yang Xin, Ning Fan, Jinzhen Cai, Liqun Wu. Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single centerBMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02661-2
9
Jia-Lin Wu, Jun-Yang Luo, Zai-Bo Jiang, Si-Bo Huang, Ge-Run Chen, Hui-Ying Ran, Qi-Yue Liang, Ming-Sheng Huang, Li-Sha Lai, Jun-Wei Chen. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapyWorld Journal of Gastroenterology 2023; 29(20): 3168-3184 doi: 10.3748/wjg.v29.i20.3168
10
Zheyu Zhou, Xiaoliang Xu, Meiling Sun, Yang Liu, Qiaoyu Liu, Chaobo Chen, Yin Yin. Conversion therapy for massive hepatocellular carcinoma: A case report and literature reviewClinical Case Reports 2023; 11(6) doi: 10.1002/ccr3.7533
11
Tatsuya Orimo, Toshiya Kamiyama, Tatsuhiko Kakisaka, Akihisa Nagatsu, Yoh Asahi, Takeshi Aiyama, Hirofumi Kamachi, Akinobu Taketomi. Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular CarcinomasAnnals of Surgical Oncology 2022; 29(13): 8436 doi: 10.1245/s10434-022-12495-z
12
Haoyang Bei, Weiheng Mai, Weifeng Chen, Mingyi Li, Yongguang Yang. Application of systemic treatment in conversion therapy options for liver cancerFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.966821
13
Yueping Liu, Meiling Sun. An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patientsClinics and Research in Hepatology and Gastroenterology 2023; 47(8): 102195 doi: 10.1016/j.clinre.2023.102195
14
Zheyu Zhou, Chaobo Chen, Meiling Sun, Xiaoliang Xu, Yang Liu, Qiaoyu Liu, Jincheng Wang, Yin Yin, Beicheng Sun. A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective studyPeerJ 2023; 11: e15950 doi: 10.7717/peerj.15950
15
Haowen Tang, Yinbiao Cao, Yiping Jian, Xuerui Li, Junfeng Li, Wenwen Zhang, Tao Wan, Zhe Liu, Wei Tang, Shichun Lu. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A reviewBioScience Trends 2022; 16(2): 130 doi: 10.5582/bst.2022.01019
16
Jia-Yi Wu, Jun-Yi Wu, De-Yi Liu, Han Li, Shao-Wu Zhuang, Bin Li, Jian-Yin Zhou, Jing-Yao Huang, Zhi-Bo Zhang, Shu-Qun Li, Mao-Lin Yan, Yao-Dong Wang. Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?Journal of Hepatocellular Carcinoma 2023; : 2161 doi: 10.2147/JHC.S442341
17
Ren Ziwang, Feng Guiling, Feng Xu, Liu Zhu, Li Bing, Du Yong. Comparative Study of CT and MR Guided Microwave Ablation in the Treatment of Para-vascular VX2 Liver Tumor Model in RabbitsCurrent Medical Imaging Formerly Current Medical Imaging Reviews 2023; 20 doi: 10.2174/1573405620666230908111713
18
Yining Wu, Shenjian Ou, Xiwen Liao, Chuangye Han, Chengkun Yang, Wei Qin, Yufeng Tan, Quan Lao, Tao Peng, Xinping Ye. Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case ReportPharmacogenomics and Personalized Medicine 2023; : 111 doi: 10.2147/PGPM.S376596